Seer Stock
Seer, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Omid C. Farokhzad
- Employees
- 124
- Market cap
- $112 M
- IPO
- 04/12/2020
- Web
- seer.bio
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and…
Seer stock: price history
1D
-0.5%
1W
-7.3%
1M
+6.8%
6M
+1.5%
YTD
+10.9%
1Y
-8.1%
2Y
+2.5%
5Y
-93.8%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~64% stronger price swings than usual
Ask the agents about Seer
Analyst assessment of Seer
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
1
BUY
2
HOLD
1
SELL
0
STRONG SELL
4
TOTAL · Hold
As of: 13/08/2024
Seer stock metrics
P/E
-1.66
P/B
0.5
EV/EBITDA
-1.73
RETURN ON EQUITY
-7.5%
NET MARGIN
-544.8%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.1%
FLOAT SHARES
40,464,207
AVG. DAILY VOLUME (30D)
262,575
Insider transactions (SEC)
Horn David R.
Roelofs Nicolas H PHD
Nishar Dipchand
Ro Isaac
Gulyani Meeta
Institutional holders
Comparable stocks
Frequently asked questions about Seer stock
What does Seer do?
Seer, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Omid C. Farokhzad, the company employs around 124 people.
The IPO was on 04/12/2020; the stock trades on NASDAQ under the ticker SEER.
What do analysts say about Seer stock?
4 analysts rate the stock, the consensus is Hold (as of 13/08/2024).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Seer report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 64% stronger than usual.
Does Seer pay a dividend?
No, Seer currently does not pay a dividend.
Which stocks are comparable to Seer?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Seer stock analyzed?
Clicking "Analyze stock" lets five strategies assess Seer against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.